Pulmonary sclerosing hemangioma （PSH）, a thoracic tumor, was first described by Liebow and Hubbell in 1956. Recently, immunohistochemical evidence and characterization of antibodies have clarified that PSHs are true...Pulmonary sclerosing hemangioma （PSH）, a thoracic tumor, was first described by Liebow and Hubbell in 1956. Recently, immunohistochemical evidence and characterization of antibodies have clarified that PSHs are true tumors. They are mainly composed of epithelial cells （Type II pneumocytes） aligned in different directions and accompanied by proliferation and reaction of other components.展开更多
To the Editor： Epidermal growth overexpressed in non-small cell factor receptor （EGFR） is lung cancer （NSCLC） and contains a tyrosine kinase inhibitor （TKI） domain which acts as an important therapeutic target....To the Editor： Epidermal growth overexpressed in non-small cell factor receptor （EGFR） is lung cancer （NSCLC） and contains a tyrosine kinase inhibitor （TKI） domain which acts as an important therapeutic target. Previous studies have observed the efficacy of EGFR-TKIs in the most commonly targeted exon mutations （19 and 21）. This study was to investigat the pathologic features of uncommon EGFR mutations and the clinical efficacies of EGFR-TKIs treatment.展开更多
文摘Pulmonary sclerosing hemangioma （PSH）, a thoracic tumor, was first described by Liebow and Hubbell in 1956. Recently, immunohistochemical evidence and characterization of antibodies have clarified that PSHs are true tumors. They are mainly composed of epithelial cells （Type II pneumocytes） aligned in different directions and accompanied by proliferation and reaction of other components.
文摘To the Editor： Epidermal growth overexpressed in non-small cell factor receptor （EGFR） is lung cancer （NSCLC） and contains a tyrosine kinase inhibitor （TKI） domain which acts as an important therapeutic target. Previous studies have observed the efficacy of EGFR-TKIs in the most commonly targeted exon mutations （19 and 21）. This study was to investigat the pathologic features of uncommon EGFR mutations and the clinical efficacies of EGFR-TKIs treatment.
